Pentoxifylline

Generic Name
Pentoxifylline
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C13H18N4O3
CAS Number
6493-05-6
Unique Ingredient Identifier
SD6QCT3TSU
Background

Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated...

Indication

Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.

Associated Conditions
Intermittent Claudication, Venous Leg Ulcer (VLU), Severe alcoholic liver disease
Associated Therapies
-

Pneumonitis Prevention Protocol Using Pentoxifylline and Α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation

First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
150
Registration Number
NCT06634056
Locations
🇨🇦

University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Pentoxifylline Role Against Chemotherapy-induced Neuropathy

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2024-08-20
Last Posted Date
2024-08-20
Lead Sponsor
Beni-Suef University
Target Recruit Count
72
Registration Number
NCT06562998
Locations
🇪🇬

University Hospital, Banī Suwayf, Beni-Suef, Egypt

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-07-10
Last Posted Date
2024-07-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
295
Registration Number
NCT06494111
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis

First Posted Date
2024-05-20
Last Posted Date
2024-05-20
Lead Sponsor
Tanta University
Target Recruit Count
75
Registration Number
NCT06422000
Locations
🇪🇬

Tanta University, Tanta, El Gharbia, Egypt

Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-04-03
Last Posted Date
2024-04-03
Lead Sponsor
The First Hospital of Hebei Medical University
Target Recruit Count
200
Registration Number
NCT06344390
Locations
🇨🇳

BHan, Shijiazhuang, China

Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial

First Posted Date
2024-03-27
Last Posted Date
2024-07-26
Lead Sponsor
Ziauddin University
Target Recruit Count
30
Registration Number
NCT06332612
Locations
🇵🇰

Ziauddin University, Karachi, Sindh, Pakistan

Efficacy of Intralesional Injection of Pentoxifylline, Platelet-Rich Plasma, and Combined Pentoxifylline With Platelet-Rich Plasma in Patients With Atrophic Acne Scars

First Posted Date
2024-03-20
Last Posted Date
2024-03-20
Lead Sponsor
Sohag University
Target Recruit Count
75
Registration Number
NCT06319768
Locations
🇪🇬

Sohag university Hospital, Sohag, Egypt

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of Both N-acetylcysteine and Pentoxifylline Supplementation in Patients With Hepatic and Post Hepatic Jaundice

First Posted Date
2024-02-01
Last Posted Date
2024-11-22
Lead Sponsor
Tanta University
Target Recruit Count
66
Registration Number
NCT06236165
Locations
🇪🇬

Faculty of Pharmacy, Tanta University, Tanta, Egypt

Effect of Pentoxifylline on Preventing Chemotherapy-induced Mucositis in Patients With Breast Cancer

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2024-01-02
Last Posted Date
2024-03-15
Lead Sponsor
Mansoura University
Target Recruit Count
80
Registration Number
NCT06186700
Locations
🇪🇬

Oncology Center of Mansoura University, Mansoura, Egypt

© Copyright 2024. All Rights Reserved by MedPath